Charles River Laboratories International, Inc. (NYSE:CRL) Shares Bought by LS Investment Advisors LLC

LS Investment Advisors LLC increased its position in Charles River Laboratories International, Inc. (NYSE:CRL) by 17.1% during the second quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 3,971 shares of the medical research company’s stock after buying an additional 580 shares during the period. LS Investment Advisors LLC’s holdings in Charles River Laboratories International were worth $402,000 as of its most recent SEC filing.

Other institutional investors also recently made changes to their positions in the company. Cardinal Capital Management increased its position in shares of Charles River Laboratories International by 1.1% in the first quarter. Cardinal Capital Management now owns 7,035 shares of the medical research company’s stock worth $633,000 after buying an additional 76 shares during the last quarter. State Treasurer State of Michigan boosted its stake in Charles River Laboratories International by 0.5% in the first quarter. State Treasurer State of Michigan now owns 19,200 shares of the medical research company’s stock valued at $1,727,000 after buying an additional 100 shares during the period. Utah Retirement Systems boosted its stake in Charles River Laboratories International by 1.2% in the first quarter. Utah Retirement Systems now owns 8,597 shares of the medical research company’s stock valued at $773,000 after buying an additional 100 shares during the period. Massmutual Trust Co. FSB ADV boosted its stake in shares of Charles River Laboratories International by 5.0% in the first quarter. Massmutual Trust Co. FSB ADV now owns 2,739 shares of the medical research company’s stock worth $246,000 after buying an additional 130 shares during the last quarter. Finally, Charter Trust Co. boosted its stake in shares of Charles River Laboratories International by 4.6% in the first quarter. Charter Trust Co. now owns 3,030 shares of the medical research company’s stock worth $272,000 after buying an additional 134 shares during the last quarter. Hedge funds and other institutional investors own 93.79% of the company’s stock.

Shares of Charles River Laboratories International, Inc. (NYSE:CRL) traded up 0.27% during mid-day trading on Friday, reaching $99.98. The company had a trading volume of 321,047 shares. The stock has a market capitalization of $4.76 billion, a P/E ratio of 26.35 and a beta of 1.02. Charles River Laboratories International, Inc. has a 52-week low of $67.20 and a 52-week high of $102.32. The company’s 50-day moving average is $99.58 and its 200 day moving average is $92.39.

Charles River Laboratories International (NYSE:CRL) last released its quarterly earnings results on Wednesday, August 9th. The medical research company reported $1.29 EPS for the quarter, topping analysts’ consensus estimates of $1.22 by $0.07. Charles River Laboratories International had a net margin of 10.13% and a return on equity of 27.02%. The business had revenue of $469.13 million for the quarter, compared to analyst estimates of $458.25 million. During the same period last year, the firm earned $1.20 earnings per share. Charles River Laboratories International’s revenue for the quarter was up 8.1% compared to the same quarter last year. Analysts anticipate that Charles River Laboratories International, Inc. will post $5.10 EPS for the current fiscal year.

Charles River Laboratories International declared that its Board of Directors has initiated a share buyback program on Wednesday, May 10th that permits the company to repurchase $150.00 million in outstanding shares. This repurchase authorization permits the medical research company to reacquire shares of its stock through open market purchases. Stock repurchase programs are often a sign that the company’s board believes its shares are undervalued.

ILLEGAL ACTIVITY NOTICE: This piece of content was originally posted by Community Financial News and is the property of of Community Financial News. If you are accessing this piece of content on another domain, it was illegally copied and republished in violation of US and international trademark and copyright legislation. The correct version of this piece of content can be read at https://www.com-unik.info/2017/08/19/charles-river-laboratories-international-inc-nysecrl-position-raised-by-ls-investment-advisors-llc-updated-updated.html.

CRL has been the subject of several analyst reports. Zacks Investment Research cut Charles River Laboratories International from a “buy” rating to a “hold” rating in a research note on Tuesday, July 25th. Citigroup Inc. reaffirmed a “neutral” rating and set a $104.00 price target (up from $91.00) on shares of Charles River Laboratories International in a report on Wednesday, June 28th. Jefferies Group LLC reaffirmed a “buy” rating and set a $106.00 price target on shares of Charles River Laboratories International in a report on Friday, April 21st. Credit Suisse Group reissued a “neutral” rating and issued a $95.00 target price (up from $89.00) on shares of Charles River Laboratories International in a report on Tuesday, June 6th. Finally, BidaskClub downgraded Charles River Laboratories International from a “strong-buy” rating to a “buy” rating in a report on Monday, July 31st. One analyst has rated the stock with a sell rating, five have given a hold rating and four have given a buy rating to the stock. The stock currently has an average rating of “Hold” and an average price target of $96.94.

In related news, Director George Massaro sold 3,830 shares of Charles River Laboratories International stock in a transaction that occurred on Monday, July 17th. The shares were sold at an average price of $100.81, for a total transaction of $386,102.30. Following the sale, the director now directly owns 18,731 shares in the company, valued at approximately $1,888,272.11. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. Also, insider David Ross Smith sold 2,552 shares of Charles River Laboratories International stock in a transaction that occurred on Monday, August 14th. The stock was sold at an average price of $67.10, for a total transaction of $171,239.20. Following the sale, the insider now owns 11,671 shares in the company, valued at $783,124.10. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 81,921 shares of company stock worth $8,017,651. 2.20% of the stock is owned by insiders.

Charles River Laboratories International Company Profile

Charles River Laboratories International, Inc is an early-stage contract research company. The Company is engaged in laboratory animal medicine and science (research model technologies) and develop a portfolio of discovery and safety assessment services, both good laboratory practice (GLP) and non-GLP, which supports its clients from target identification through non-clinical development.

Institutional Ownership by Quarter for Charles River Laboratories International (NYSE:CRL)

What are top analysts saying about Charles River Laboratories International Inc.? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Charles River Laboratories International Inc. and related companies.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit